Agreed. Given that (1) we have DCVax-L and it applies to all solid tumors, (2) we have DCVax direct in the pipeline, and (3) we have the technology to more efficiently manufacture DCVax, I do not see how we could ONLY be worth $10-12B. How do you go about valuing all of that, I have no idea, but to me it would seem to be worth way more than 10-12.
Market Data 
Markets 
AI
